Biomerieux SA
PAR:BIM

Watchlist Manager
Biomerieux SA Logo
Biomerieux SA
PAR:BIM
Watchlist
Price: 115.9 EUR 0.35% Market Closed
Market Cap: 13.7B EUR

Biomerieux SA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Biomerieux SA
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Biomerieux SA
PAR:BIM
Revenue
€4B
CAGR 3-Years
6%
CAGR 5-Years
8%
CAGR 10-Years
9%
Edap Tms SA
NASDAQ:EDAP
Revenue
€60.4m
CAGR 3-Years
13%
CAGR 5-Years
9%
CAGR 10-Years
10%
Carmat SA
PAR:ALCAR
Revenue
€5.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biosynex SA
PAR:ALBIO
Revenue
€104m
CAGR 3-Years
-32%
CAGR 5-Years
26%
CAGR 10-Years
45%
Visiomed Group SA
PAR:ALVMG
Revenue
€13.7m
CAGR 3-Years
-10%
CAGR 5-Years
9%
CAGR 10-Years
2%
Amplitude Surgical SA
PAR:AMPLI
Revenue
€108.5m
CAGR 3-Years
12%
CAGR 5-Years
1%
CAGR 10-Years
N/A

Biomerieux SA
Glance View

Economic Moat
None
Market Cap
13.7B EUR
Industry
Health Care

In the world of clinical diagnostics, bioMérieux SA emerges as a formidable player, weaving together a tapestry of innovation, precision, and reliability. Founded in 1963 by Alain Mérieux, the company has its roots deeply embedded in Lyon, France, where a legacy of scientific prowess meets a global vision. bioMérieux specializes in in vitro diagnostics, creating a broad array of products and solutions that essentially serve as the medical community’s early warning systems. Their expertise spans across fields like microbiology, immunoassays, and molecular biology, where they craft diagnostic kits and automated instruments that empower healthcare providers to detect and prevent diseases with remarkable accuracy. By tapping into a robust network of research and development, bioMérieux collaborates with hospitals, laboratories, and public health organizations worldwide to address both routine and critical diagnostic needs. At the heart of bioMérieux’s business is its razor-sharp focus on infectious diseases, a sector that has seen accelerated growth in recent years, particularly with the advent of global health challenges such as the COVID-19 pandemic. The firm generates revenue through the sale of its diagnostic solutions and related services, offering comprehensive testing systems that include reagents and consumables, maintenance contracts, and training for laboratory professionals. Their continuous investment in innovation allows them to expand their product portfolio and tailor solutions to the evolving needs of the healthcare industry. By maintaining a pulse on global health trends and investing in cutting-edge technologies, bioMérieux not only secures its market position but also plays a crucial role in strengthening global public health infrastructure.

BIM Intrinsic Value
113.16 EUR
Overvaluation 2%
Intrinsic Value
Price

See Also

What is Biomerieux SA's Revenue?
Revenue
4B EUR

Based on the financial report for Dec 31, 2024, Biomerieux SA's Revenue amounts to 4B EUR.

What is Biomerieux SA's Revenue growth rate?
Revenue CAGR 10Y
9%

Over the last year, the Revenue growth was 8%. The average annual Revenue growth rates for Biomerieux SA have been 6% over the past three years , 8% over the past five years , and 9% over the past ten years .

Back to Top